Janumet XR · DIN 02416786 · 50 mg & 500 mg · extended release tablet
General benefitMarketed · checked November 17, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Janumet XR · DIN 02416786
Manufacturer: Merck Canada Inc.; listing date 2016-12-22
Health Canada: Marketed since 2015-01-13 · brand JANUMET XR · ATC A10BD07 METFORMIN AND SITAGLIPTIN · form Tablet (extended-release) · route Oral · ingredients SITAGLIPTIN (SITAGLIPTIN PHOSPHATE MONOHYDRATE) 50 MG, METFORMIN HYDROCHLORIDE 500 MG · company Merck canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02416786)
Source record
DIN 02416786: Janumet XR
Raw flags: chronicUseMed=Y, insOH=Y, sec3=Y
Item: 682002061; group id 757; item number 1858; lccId None; manufacturer id MEK
Source form: ER Tab; strength: 50mg & 500mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit); diabetes medication flag
Source prices (unrounded): $1.8496; ministry $0.8893
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02416786
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90139
Therapeutic Notes (formulary)
Treatment of Type 2 diabetes in patients on maximally tolerated doses of metformin who have:
. Inadequate glycemic control (defined as HbA1c greater than 0.07) and intolerance or contraindication to a sulfonylurea; OR
. Inadequate glycemic control (HbA1c greater than 0.07) and on maximal doses of sulfonylurea and for whom insulin is not an option.
Interchangeable products
Apo-Sitagliptin/Metformin XR · DIN 02506270 · $0.8893
Sandoz Sitagliptin-Metformin XR · DIN 02529106 · $0.8893
Shortage status: not checked (no credentials)